AIM2 and neoplasm: In a recent study it was found that Chimeric Antigen Receptor T cell (CAR-T) treatment led to the activation of AIM2 in macrophages and the ensuing release of IL-1β both by inducing the α1- adrenergic receptor (α1-AR)-mediated adrenergic signaling and by releasing tumor cell DNA [107].